Jasper Therapeutics, Inc. (JSPR)
0.6932
-0.02
(-2.28%)
USD |
NASDAQ |
Sep 09, 14:39
Jasper Therapeutics Enterprise Value : 12.46M for Sept. 8, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 08, 2026 | 12.46M |
| September 04, 2026 | 12.44M |
| September 03, 2026 | 11.81M |
| September 02, 2026 | 12.33M |
| September 01, 2026 | 12.13M |
| August 31, 2026 | 12.51M |
| August 28, 2026 | 12.19M |
| August 27, 2026 | 12.17M |
| August 26, 2026 | 12.70M |
| August 25, 2026 | 12.76M |
| August 24, 2026 | 12.82M |
| August 21, 2026 | 12.64M |
| August 20, 2026 | 11.95M |
| August 19, 2026 | 13.50M |
| August 18, 2026 | 13.60M |
| August 17, 2026 | 16.19M |
| August 14, 2026 | 14.72M |
| August 13, 2026 | 16.77M |
| August 12, 2026 | 15.67M |
| August 11, 2026 | 17.62M |
| August 10, 2026 | 14.99M |
| August 07, 2026 | 12.46M |
| August 06, 2026 | 10.68M |
| August 05, 2026 | 11.07M |
| August 04, 2026 | 11.23M |
| Date | Value |
|---|---|
| August 03, 2026 | 9.564M |
| July 31, 2026 | 10.23M |
| July 30, 2026 | 9.971M |
| July 29, 2026 | 9.390M |
| July 28, 2026 | 10.31M |
| July 27, 2026 | 12.03M |
| July 24, 2026 | 11.87M |
| July 23, 2026 | 13.01M |
| July 22, 2026 | 13.45M |
| July 21, 2026 | 14.16M |
| July 20, 2026 | 15.40M |
| July 17, 2026 | 17.39M |
| July 16, 2026 | 14.27M |
| July 15, 2026 | 11.97M |
| July 14, 2026 | 12.83M |
| July 13, 2026 | 9.609M |
| July 10, 2026 | 8.811M |
| July 09, 2026 | 8.864M |
| July 08, 2026 | 6.989M |
| July 07, 2026 | 6.065M |
| July 06, 2026 | 5.624M |
| July 02, 2026 | 4.566M |
| July 01, 2026 | 5.301M |
| June 30, 2026 | 4.360M |
| June 29, 2026 | -1.634M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Agenus, Inc. | 581.29M |
| Amgen, Inc. | 255.86B |
| Anika Therapeutics, Inc. | 268.42M |
| BioCryst Pharmaceuticals, Inc. | 2.798B |
| Imunon, Inc. | 8.166M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -2.76M |
| Total Expenses (Quarterly) | 2.76M |
| EPS Diluted (Quarterly) | -0.0962 |
| Earnings Yield | -228.1% |
| Normalized Earnings Yield | -299.55 |